Dante Genomics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Dante Genomics - overview
Established
2016
Location
New York, NY, US
Primary Industry
Biotechnology
About
Based in New York, US, and founded in 2016 by Andrea Riposati (CEO), and Mattia Capulli, Dante Genomics is a genome diagnostic and precision medicine company that offers genetic sequencing information to enable healthcare professionals provide customized therpaies. In May 2022, Dante Genomics raised grant funding from investor Ministry of Economic Development. The firm offers software solutions that employ artificial intelligence (AI) and machine learning (ML) models to provide customized genome sequencing analysis and provide actionable insights to healthcare professionals. The firm’s services include whole genome testing, clinical lab-in-a-box, population genomics and dante platform analysis that analyze rare diseases and provides interpretations.
The company intends to use the May 2022 funding to develop and pilot the first fully-CE-IVD, clinically approved whole genome sequencing (WGS) test for the citizens of Italy to be named the Dante Citizen Test.
Current Investors
StartUp Health, Ministry of Economic Development
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Diagnostic, Medical & Imaging Laboratories, Medical Software, Application Integration Software, Analytics & Performance Software
Website
www.dantegenomics.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Dante Genomics - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.